Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years

Gastroenterology

Volumn 141, Issue 4, 2011, Pages

  Deugnier, Yves ^a   Turlin, Bruno ^a   Ropert, Martine ^a   Cappellini, M Domenica ^b   Porter, John B ^c   Giannone, Vanessa ^d   Zhang, Yiyun ^d   Griffel, Louis ^d   Brissot, Pierre ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cirrhosis; Clinical Trial; Liver Disease; Therapy

Indexed keywords

DEFERASIROX; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CHILD; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; IRON OVERLOAD; LIVER FIBROSIS; LIVER FUNCTION; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80052691105     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.06.065     Document Type: Article

References (44)

1. N.C. Andrews Disorders of iron metabolism N Engl J Med 341 1999 1986 1995 (Pubitemid 30010408)
2. J.P. Kushner, J.P. Porter, and N.F. Olivieri Secondary iron overload Hematology Am Soc Hematol Educ Program 2001 47 61
3. F.A. Ardalan, M.R. Osquei, and M.N. Toosi Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study BMC Gastroenterol 4 2004 17
4. E. Angelucci, P. Muretto, and A. Nicolucci Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation Blood 100 2002 17 21 (Pubitemid 35177422)
5. V. Berdoukas, T. Bohane, and V. Tobias Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy Hematol J 5 2005 572 578 (Pubitemid 40309622)
6. I.R. Wanless, G. Sweeney, and A.P. Dhillon Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia Blood 100 2002 1566 1569 (Pubitemid 34925128)
7. S.F. Wu, C.T. Peng, and K.H. Wu Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients Hemoglobin 30 2006 215 218
8. P. Farci, T. Roskams, and L. Chessa Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis Gastroenterology 126 2004 1740 1749 (Pubitemid 38736339)
9. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832 (Pubitemid 27129209)
10. Y. Shiratori, F. Imazeki, and M. Moriyama Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann Intern Med 132 2000 517 524 (Pubitemid 30171890)
11. K. Das, and A. Chowdhury Hepatic fibrosis: can we treat it clinically? Trop Gastroenterol 29 2008 76 83
12. D. Povero, C. Busletta, and E. Novo Liver fibrosis: a dynamic and potentially reversible process Histol Histopathol 25 2010 1075 1091
13. M. Barry, D.M. Flynn, and E.A. Letsky Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress Br Med J 2 1974 16 20
14. M.D. Cappellini, A. Cohen, and A. Piga A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia Blood 107 2006 3455 3462
15. J. Porter, R. Galanello, and G. Saglio Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study Eur J Haematol 80 2008 168 176
16. M.D. Cappellini, S. Perrotta, and L. Agaoglu Efficacy and safety of deferasirox (Exjade®) in patients with β-thalassemia major treated for up to 5 years Blood 114 22 2009 abst 4063
17. Y. Aydinok, L. Agaoglu, and M. Bejaoui Growth and development of pediatric patients with beta-thalassaemia treated with deferasirox for up to 5 years Haematologica 95 Suppl 2 2010 abst 1040
18. P. Brissot, B. Turlin, and G.-L. Forni Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia Blood 106 11 2005 abst 823
19. M. Barry, and S. Sherlock Measurement of liver-iron concentration in needle-biopsy specimens Lancet 1 1971 100 103
20. E. Angelucci, G.M. Brittenham, and C.E. McLaren Hepatic iron concentration and total body iron stores in thalassemia major N Engl J Med 343 2000 327 331 (Pubitemid 30616698)
21. M.J. Soriano-Cubells, and L. Aparisi-Querada Rapid determination of copper, iron and zinc in liver biopsies Atomic Spectrosc 5 1984 217 222
22. N.F. Olivieri, and G.M. Brittenham Iron-chelating therapy and the treatment of thalassemia Blood 89 1997 739 761 (Pubitemid 27121266)
23. Y.M. Deugnier, O. Loreal, and B. Turlin Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations Gastroenterology 102 1992 2050 2059
24. K. Ishak, A. Baptista, and L. Bianchi Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696 699
25. The METAVIR Cooperative Study Group P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C Hepatology 24 1996 289 293 (Pubitemid 26260021)
26. L. Falize, A. Guillygomarc'h, and M. Perrin Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases Hepatology 44 2006 472 477 (Pubitemid 44214887)
27. P. Muretto, E. Angelucci, and G. Lucarelli Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation Ann Intern Med 136 2002 667 672 (Pubitemid 34462679)
28. N.F. Olivieri, G.M. Brittenham, and C.E. McLaren Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major N Engl J Med 339 1998 417 423 (Pubitemid 28377682)
29. B.Z. Zhu, R. Har-El, and N. Kitrossky New modes of action of desferrioxamine: scavenging of semiquinone radical and stimulation of hydrolysis of tetrachlorohydroquinone Free Radic Biol Med 24 1998 360 369 (Pubitemid 28008815)
30. P.L. Greenberg, C.A. Koller, and Z.I. Cabantchik Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes Leuk Res 34 2010 1560 1565
31. J. Porter Pathophysiology of iron overload Hematol Oncol Clin North Am 19 Suppl 1 2005 7 12
32. A.F. List, M.R. Baer, and D. Steensma Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS) Blood 110 11 2007 abst 1470
33. P.D. Jensen, F.T. Jensen, and T. Christensen Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias Blood 101 2003 91 96 (Pubitemid 36025892)
34. G.J. Bruin, T. Faller, and H. Wiegand Pharmacokinetics, distribution, metabolism and excretion of deferasirox and its iron complex in rats Drug Metab Dispos 36 2008 2523 2538
35. E. Messa, S. Carturan, and C. Maffé Deferasirox is a powerful NF-kB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from intracellular iron chelation and reactive oxygen species scavenging Haematologica 95 2010 1308 1316
36. H. Fujimoto, C.N. D'Alessandro-Gabazza, and M.S. Palanki Inhibition of nuclear factor-kappaB in T cells suppresses lung fibrosis Am J Respir Crit Care Med 176 2007 1251 1260 (Pubitemid 350256479)
37. Y. Wang, M. Wu, and R. AL-Rousan Iron-induced cardiac damage: role of apoptosis and deferasirox intervention J Pharmacol Exp Ther 336 2011 56 63
38. M.D. Cappellini, J.B. Porter, and A. El-Beshlawy Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias Haematologica 95 2010 557 566
39. A. Taher, A. El-Beshlawy, and M.S. Elalfy Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study Eur J Haematol 82 2009 458 465
40. E. Vichinsky, T. Coates, and A.A. Thompson Deferasirox (Exjade®), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up Blood 112 11 2008 abst 1420
41. M.D. Cappellini, M. Elalfy, and A. El-Beshlawy Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B or C Haematogica 95 Suppl 2 2010 abst 1860
42. N. Gattermann, C. Finelli, and M. Della Porta Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study Leuk Res 34 2010 1143 1150
43. F. Wimazal, T. Nösslinger, and C. Baumgartner Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes Eur J Clin Invest 39 2009 406 411
44. P. Brissot, Y. Deugnier, and P. Cianciulli Dose-dependent reductions in serum transaminases and ferritin levels correlate during long-term therapy with deferasirox (Exjade, ICL670) Book of Abstracts International BioIron Society 2007 abst 105